Importantly, the protective effect of SGLT-2 inhibitors against hospitalization for heart failure across both groups in our study supports mechanistic hypotheses regarding volume regulation, myocardial remodeling, and renal hemodynamic stabilization [23,24]. The gene discussed is SLC5A2; the disease is heart failure.